Stifel Maintains Buy on SpyGlass Pharma, Raises Price Target to $44

Benzinga · 21h ago
Stifel analyst Tom Stephan maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $44.